Thus, inhibitors of SHP2 can block the RTK/RAS/MAPK signaling pathways and inhibit the growth and proliferation of tumor cells driven by RTK or with KRAS, BRAF Class 3 and NF1 loss of function mutations.245, 246, 247, 248, 409. Here, KRAS is linked to neoplasm.